Pacer Advisors Inc. Reduces Stock Holdings in Lantheus Holdings, Inc. $LNTH

Pacer Advisors Inc. lowered its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 97.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,704 shares of the medical equipment provider’s stock after selling 247,589 shares during the quarter. Pacer Advisors Inc.’s holdings in Lantheus were worth $584,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the stock. Abel Hall LLC lifted its position in Lantheus by 4.6% in the first quarter. Abel Hall LLC now owns 3,915 shares of the medical equipment provider’s stock valued at $297,000 after acquiring an additional 172 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares during the last quarter. Vident Advisory LLC increased its position in shares of Lantheus by 0.5% during the fourth quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock worth $2,979,000 after purchasing an additional 230 shares in the last quarter. Farther Finance Advisors LLC increased its position in shares of Lantheus by 71.4% during the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 275 shares in the last quarter. Finally, Resona Asset Management Co. Ltd. lifted its holdings in shares of Lantheus by 35.7% in the 4th quarter. Resona Asset Management Co. Ltd. now owns 1,109 shares of the medical equipment provider’s stock valued at $75,000 after purchasing an additional 292 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Trading Up 0.0%

NASDAQ LNTH opened at $100.98 on Tuesday. The stock has a market capitalization of $6.59 billion, a P/E ratio of 24.39 and a beta of -0.03. Lantheus Holdings, Inc. has a 52-week low of $49.67 and a 52-week high of $111.86. The firm has a 50-day moving average price of $104.17 and a 200 day moving average price of $88.39. The company has a quick ratio of 2.89, a current ratio of 3.06 and a debt-to-equity ratio of 0.43.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The company had revenue of $388.18 million for the quarter, compared to analyst estimates of $363.23 million. During the same quarter in the previous year, the company earned $1.57 EPS. The firm’s revenue for the quarter was up 2.7% compared to the same quarter last year. Equities research analysts expect that Lantheus Holdings, Inc. will post 4.5 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Leerink Partners set a $102.50 target price on Lantheus in a research report on Monday, August 3rd. Truist Financial lowered Lantheus from a “buy” rating to a “hold” rating and cut their price target for the stock from $125.00 to $102.50 in a research report on Monday, August 3rd. Citigroup reiterated an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. The Goldman Sachs Group reissued a “neutral” rating and issued a $94.00 price objective on shares of Lantheus in a report on Thursday, May 7th. Finally, TD Cowen lowered shares of Lantheus from a “buy” rating to a “hold” rating and lowered their target price for the stock from $110.00 to $102.50 in a research report on Monday, August 3rd. Five equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $108.11.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.